AIDS-Related Complex

MUNICH--( BUSINESS WIRE )--AIDS Healthcare Foundation ( AHF ) will host an in-person and virtual press conference at the AHF booth (#111) during the 2024 International AIDS Conference (AIDS 2024) on Tuesday, July 23 at 13:15 CEST (7:15 a.m. US EDT) in Munich, Germany, at the Messe München Convention Center and virtually via Zoom . During the press conference, public health advocates and experts will reiterate how global access to affordable medicines is being subverted by the pursuit of profit-at-all-cost strategy employed by Gilead Sciences and other Big Pharma companies. Unabated corporate greed keeps millions of people in low- and middle-income countries from accessing lifesaving medicines they need to stay alive and healthy. WHAT: AHF to host LIVE and VIRTUAL GREEDY GILEAD PRESS CONFERENCE during the International AIDS Conference 2024 (AIDS 2024). WHEN: Tuesday, July 23 at 13:15 CEST (7:15 a.m. US EDT) – Munich, Germany WHERE: AHF AIDS 2024 BOOTH 111 at Messe München Convention Center and VIRTUALLY VIA ZOOM . WHO: Public health experts and advocates : Dr. V. Sam Prasad , Country Program Director, AHF India Cares Dr. Victor Popoola , Medical Manager, AHF Sierra Leone Guillermina Alaniz , Director of Global Advocacy & Policy, AHF John Farina , Associate Director of Advocacy, AHF NEWS DESK NOTE & B-ROLL VISUALS Press conference will be live streamed on Zoom & Facebook from the AHF AIDS 2024 conference booth. Visit the AHF FACEBOOK page or ZOOM LINK to watch. Visit www.gilead.org for more information about the Greedy Gilead campaign. MEDIA CONTACTS: Denys Nazarov, Director of Global Policy & Communications, AHF, +1.323.308.1829, denys.nazarov@ahf.org Brian Shepherd, Associate Director of Global Communications, AHF, +1.808.382.8570, brian.shepherd@ahf.org "Gilead has harmed people living with HIV worldwide for two-plus decades by securing continual patents, known as 'evergreening,' and generating billions of dollars through monopolies on some of the most effective and well-tolerated antiretroviral HIV drugs. There's no better place than AIDS 2024 to make everyone aware and demand that Gilead choose lives over its greedy tactics that limit access to medicines people worldwide desperately need," said AHF Chief of Global Advocacy & Policy Terri Ford. "As a leading global HIV/AIDS organization with more than 2 million patients in care in 47 countries, AHF is taking a stand and calling out Gilead so that governments and decision-makers everywhere put collective pressure on it to prioritize lives over obscenely high profits." Advocates will also highlight the fact that HIV/AIDS is not over—as it remains a pandemic and a significant global public health crisis responsible for 630,000 deaths every year globally. According to UNAIDS, more than 39 million people were living with HIV in 2022, including 1.3 million people who had newly acquired the virus. Since the AIDS pandemic started, more than 40 million people have died from AIDS-related illnesses. AIDS Healthcare Foundation (AHF) is a global non-profit organization providing cutting-edge medicine and advocacy to more than 2 million people in 47 countries worldwide in Africa, the Americas, the Asia/Pacific Region and Europe. We are currently the largest non-profit provider of HIV/AIDS medical care in the world. To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare

LOS ANGELES--( BUSINESS WIRE )--In honor of World AIDS Day, AIDS Healthcare Foundation (AHF), the world’s largest HIV/AIDS health care organization, has taken over the largest digital sign on the West Coast. AHF’s message – “1.9 Million Lives in Care” – will show every couple minutes all day Friday on three sides of the building located on Broadway off the I-10 in downtown Los Angeles. Freeway commuters have a clear view of the building’s display. While 29.8 million people living with HIV – of 39 million worldwide – now receive lifesaving treatment, the fight against HIV/AIDS continues. AHF will reach two million lives in care by early 2024. In addition to street level photographs available now, drone images and additional images from the freeway will be available for distribution throughout the day. PJX Media secured the placement for AHF. AIDS Healthcare Foundation (AHF) and more than 40 AHF country teams are holding commemorative events Friday to honor all who have lost their lives to AIDS-related illnesses, support those who carry on the fight, and unite people globally in battling one of the world’s deadliest infectious diseases. AHF mobilizers in the U.S. will host 26 events in 21 cities across the country, promoting testing, education, and open conversation around HIV/AIDS awareness and prevention. AHF is continuing its longstanding tradition of hosting a high-profile World AIDS Day concert and awareness event as global icon Janet Jackson will perform a full-length show at NRG Arena in Houston, TX Friday night. AHF also will honor American actor Blair Underwood with its Lifetime Achievement Award for his efforts as a powerful voice in the fight against HIV/AIDS in the U.S. and abroad for more than three decades. “The global HIV/AIDS response has fallen short over recent years due to COVID-19 and other competing global crises,” said Michael Weinstein , AHF President and Cofounder. “AHF calls on all nations and global public health institutions to ensure the adequate resources and political will are available to fight HIV/AIDS. On World AIDS Day, the world must remember – it’s not over.” AIDS Healthcare Foundation (AHF), the world’s largest HIV/AIDS healthcare organization, provides cutting-edge medicine and advocacy to more than 1.9 million individuals across 45 countries, including the U.S. and in Africa, Latin America/Caribbean, the Asia/Pacific Region, and Eastern Europe. To learn more about AHF, visit us online at AIDShealth.org , find us on Facebook , follow us on Instagram , Twitter , and TikTok , and subscribe to our AHFter Hours podcast.

BAAR, Switzerland--(BUSINESS WIRE)-- Stallergenes Greer, a biopharmaceutical company specialising in the diagnosis and treatment of respiratory allergies, announced today the initiation of a Phase III clinical study (YOBI, YOung patients and BIrch allergy) to confirm the safety and efficacy of Staloral® Birch in children and adolescents with birch pollen-induced allergic rhino-conjunctivitis with or without asthma. The randomised, double-blind placebo-controlled Phase III study will involve approximately 80 sites in 12 European countries. Allergic rhino-conjunctivitis is a worldwide disease and a global health burden affecting more than 500 million people, who are at higher risk of developing rhinitis exacerbation and asthma than the general population1..Birch is among the strongest allergy-producing trees in northern Europe. The allergic potential of other trees belonging to the birch homologous group, such as alder and hazel, is also increasing steadily2. In children and adolescents, allergic rhino-conjunctivitis can lead to sleep problems, fatigue, missed school days and can complicate outdoor activities3. Individuals sensitised at a young age are also more at risk of developing asthma. The younger the children are, the higher their risk of developing asthma, which highlights the relevance of early causal treatment in paediatric patients to slow the worsening of allergy symptoms4. Allergen immunotherapy (AIT) is currently the only available therapeutic treatment that has the potential to uniquely alter the natural course of the disease5. In its liquid form, sublingual AIT can provide a needle-free and flexible treatment for children and adolescents. “Allergic rhino-conjunctivitis induced by birch and related trees can lead to a spiraling of respiratory symptoms and conditions in the paediatric population. The YOBI study will contribute to addressing a global health burden, while deepening our knowledge of AIT with the aim of improving patient outcomes for children and adolescents with birch-induced allergies,” said Professor Oliver Pfaar, International Coordinator of the YOBI study, Head of Rhinology and Allergy, Department of Otorhinolaryngology, Philipps-Universität Marburg, Germany. “Stallergenes Greer’s AIT treatments have proven their efficacy and safety in both clinical trials and the real world,” stated Michele Antonelli, CEO of Stallergenes Greer. “This paediatric Phase III study, illustrates our determination to further develop evidence-based solutions and build on robust datasets and cutting-edge research technologies to advance precision medicine combined with dose adaptation for the benefit of patients with allergies, the medical community, and health systems.” ABOUT STALORAL® Staloral® is a sublingual solution of allergen extracts for AIT. It is indicated in the treatment of seasonal or perennial allergic rhinitis, rhino-conjunctivitis and mild to moderate allergic asthma in adults and, in certain territories, in the paediatric population (children over 5 years of age). Clinical evidence of the efficacy of Staloral® is globally consistent over the clinical studies Stallergenes Greer conducted versus placebo. The effectiveness of Staloral® as a causal treatment for allergic rhino-conjunctivitis beyond clinical trials was also assessed by Stallergenes Greer’s real-world studies EfficAPSI and BREATH (Bringing Real-World Evidence to Allergy Treatment for Health). ABOUT ALLERGIC RHINITIS/ALLERGIC RHINO-CONJUNCTIVITIS Allergic rhinitis/allergic rhino-conjunctivitis (AR/ARC) is a chronic disorder of the upper airways that is caused by allergen exposure and the resulting IgE-mediated inflammation of the nose and, to a less extent, the eyes. Allergic rhinitis can notably include symptoms such as sneezing, a runny nose, wheezing, cough, itching, and watery/itchy eyes. Symptoms may be severe and significantly impact the patient’s quality of life, as well as worsen over time with progression towards asthma4. First intention symptomatic treatments such as antihistamines and nasal corticosteroids provide temporary relief to patients. The primary therapeutic goals of AIT include reducing symptoms, reducing symptomatic medication use, and improving allergy-related quality of life. AIT achieves these goals and can alter the course of the disease, with benefits persisting in many patients for several years after treatment discontinuation6. ABOUT STALLERGENES GREER INTERNATIONAL AG Headquartered in Baar (Switzerland), Stallergenes Greer International AG is a global healthcare company specialising in the diagnosis and treatment of allergies through the research, development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer International AG is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France). For more information, visit . 1. Bousquet, J., et al., Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy, 2008. 63 Suppl 86: p. 8-160. 2. Biedermann, T., et al., Birch pollen allergy in Europe. Allergy, 2019. 74(7): p. 1237-1248. 3. Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC. A survey of the burden of allergic rhinitis in Europe. Allergy. 2007;62 Suppl 85:17-25. doi:10.1111/j.1398-9995.2007.01549.x 4. Klimek, L., et al., ARIA guideline 2019: treatment of allergic rhinitis in the German health system. Allergo journal international, 2019. 28(7): p. 255-276. 5. Roberts G, Pfaar O, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018;73(4):765-798. doi:10.1111/all.13317 6. Hesse, L., et al., Allergen immunotherapy for allergic airway diseases: Use lessons from the past to design a brighter future. Pharmacology & Therapeutics, 2022: p. 108115.